This article is part of our comprehensive guide to POTS and dysautonomia.
You’ve also probably had the anxiety conversation more than once, and the deconditioning one too. As plenty of people with orthostatic symptoms spend years being told to drink more water before anybody thinks to measure their heart rate lying down and then again on standing. That’s not just you though: survey and registry data describe long delays to diagnosis, repeated misdiagnosis, and symptoms routinely put down to anxiety (but you probably already knew that) [1][2][3][4].
In February 2026, a group of cardiologists, neurologists, and autonomic specialists, published a state of the art review of POTS in Heart, Lung and Circulation, something people had been waiting for….for a long time [5]. What follows is what’s in it, what was already established before it, and where the confident version has got ahead of the evidence. That last part matters more so if you’re trying to make sense of the whole POTS EDS and MCAS overlap.
A quick note before we go further though: this post is educational. It’s not medical advice, it doesn’t replace a clinical assessment, and it shouldn’t be used to self diagnose, or to change treatment you’re already on. If you’re concerned about POTS or dysautonomia, please go work with a healthcare professional who knows your full, individual, picture. When it comes to POTS there are many, many, nuances to work around.
What Is the 2026 POTS State of the Art Review?
Now, a state of the art review isn’t “new” research, as nobody ran anything or pooled anybody else’s numbers. It’s a synthesis: experienced clinicians, pulling the existing evidence together and describing where the field stands on diagnosis, mechanisms, management, symptom burden, and of course special populations [5].
What it describes will feel pretty familiar if you live with this for literally any amount of time. Broad multisystem symptoms rather than isolated tachycardia, long diagnostic delays, very limited access to autonomic specialists (which is why it can feel a little like a post/zip code lottery), and a case for multidisciplinary care that most health systems simply just aren’t set up to deliver [5][6]. Wider registry work says much the same, including substantially reduced quality of life compared with matched populations [7][2].
Whether any of that changes what happens in a real appointment is another matter all together though. Reviews inform training and referral pathways, they don’t create clinic capacity or really caring specialists, so claims that this one will reshape POTS care are very much speculation, rather than solid evidence.
The Diagnostic Approach: What a Standing Test Can and Cannot Settle
This is the part that most needs correcting, as it keeps getting reported as a 2026 breakthrough and it really isn’t one.
A structured standing test can identify POTS in ordinary clinics. You lie down, your heart rate and blood pressure get recorded, you stand, and the measurements are repeated over the next ten minutes. A rise of 30 beats per minute or more in adults, or 40 or more in adolescents, without a sustained fall in blood pressure, alongside chronic orthostatic symptoms lasting at least three months, and other causes excluded, meets the criteria [5][8].
None of that is new though, as earlier expert consensus and reviews already supported diagnosis on orthostatic vitals, plus history in most cases. Recent reviews reinforce rather than introduce it [9][10][11]. Nor has tilt table testing been retired, by the way. It remains the specialist reference standard in several reviews and stays useful when the diagnosis is uncertain, when another autonomic disorder is suspected, or for confirmation and phenotyping [12][13][14].
So the practical version is this: you don’t have to wait years for a tilt table to be taken seriously, and a GP with a blood pressure cuff and a timer has the tools to do the first pass (no special kit, no separate waiting list). A simple test isn’t the same thing as a confident clinician, unfortunately, and awareness in primary care remains patchy. Which is a training and access problem rather than a criteria problem. Getting anywhere with hypermobility or EDS diagnosis at the moment, tends to be slow for exactly the same reasons.
Screening tools have their own limits, and hypermobility disorders also appear to be more common in POTS populations and vice versa, which is why we’ve written at length about the Beighton score and why it carries more weight in clinics than its design really justifies, if you fancy a read.
The Shift Towards What People Actually Report
Criteria built around a heart rate number miss a lot. As, People with POTS commonly have overlapping problems across fatigue, cognition, gut function and pain rather than tachycardia on its own, and consensus work has explicitly flagged that heart rate centred definitions, just don’t capture that burden [6][15][12].
Weighting reported symptoms more heavily is a reasonable response, and at this stage an unproven one sadly, as evidence is still very limited on whether broader symptom led criteria actually improve diagnostic precision or care [6].
Somewhat of a double edge sword though, as a wider net catches people who’ve been dismissed for a decade (which is great don’t get me wrong), but it risks pooling people whose physiology differs, which makes treatment planning even murkier. The numbers only version basically fails anyone whose heart rate rises just under the threshold, and something like coat hanger pain is exactly what a purely cardiac framing has no room for.
POTS Isn’t just One Condition: Understanding the Three Subtypes
POTS is better understood as a final common pathway, rather than as a single disease process. The three subtype framework, hyperadrenergic, neuropathic and hypovolemic, are widely used, and reflect genuinely different mechanisms that often coexist in the same person [12][16][17][18].
One quick caveat first, as it’s the important one: formal subtyping is not recommended at initial screening, as the tools for sorting people into these boxes are pretty limited [8]. The framework guides what to try, it isn’t a diagnostic test.
Hyperadrenergic POTS
Here the sympathetic nervous system runs hot, standing brings a sharp and often sustained heart rate rise, blood pressure that can climb rather than drop, forceful palpitations, tremor, flushing, and a physical sensation that’s very, very, easy to mistake for anxiety (and unfortunately, has left many people in the dark for many years). The physiology is recognised, including raised standing noradrenaline in a subset of people [12][16]. Our longer piece on hyperadrenergic POTS covers what tends to help and what tends to backfire, if you want to go a little deeper into this one.
This is also the subtype most often discussed alongside mast cell problems (which does seem to be getting more recognition), but, ultimately, where the story outruns the data for the moment. A clinical association has been described though. Mast cells do release substances that could “plausibly” amplify sympathetic activation. But, it’s suggestive rather than settled for the moment, and reported prevalence swings wildly with the case definition used, so treat any single percentage figure with suspicion [19][20][21]. We’ve also covered mast cell activation syndrome at great depth, and why it’s so contested separately if you want to go deeper.
Neuropathic POTS
In this one, the nerves that should tighten the blood vessels in your legs and abdomen when you stand, aren’t doing the job properly. Blood pools downwards, less of it returns to the heart, and heart rate climbs to make up the shortfall. Partial sympathetic denervation and small fibre abnormalities have both been described in POTS, which is the closest thing here to a structural finding [9][22].
Small fibres carry nociceptive input (potentially dangerous stimuli), temperature and autonomic signalling, which is why the knock on effect spreads well beyond the legs, and is so easy to misread as vague or psychological. Mottled or oddly coloured feet after standing come from the same failure of vascular tone. Now, an autoimmune contribution is an emerging hypothesis, rather than an established mechanism, and it sits among the field’s open research questions (of which there is many) [6].
Cognitive symptoms also belong here, and if that’s the part wrecking your working day, our brain fog article is worth reading on its own.
Hypovolemic POTS
Here, the circulating blood volume is genuinely low, and the hormonal system that should hold on to fluid, appears under responsive. Upright, there just simply isn’t enough volume to maintain perfusion, so the heart rate compensates. Low volume is a major mechanism in POTS and volume expansion is standard first line management [16][11]. Any precise percentage you see for how depleted plasma volume is, comes from particular studies rather than being a universal number.
Which is why salt and fluid loading transforms things for some people, and does pretty much nothing for others. This is actually, a really nuanced topic by the way, and one worth really looking into. The subtypes aren’t mutually exclusive either, and plenty of people have features of two or three at once, so there’s rarely just one lever to pull.
The EDS and Hypermobility Connection
The association between hypermobile EDS, hypermobility spectrum disorders, and POTS is one of the more solid things in here. Hypermobility is clearly overrepresented in POTS populations, particularly in specialist and paediatric clinics [9][23][24][25].
The usual explanation goes like this: blood vessels are partly connective tissue, so altered connective tissue means more compliant veins, easier pooling, less venous return and a heart rate that compensates. That fits what clinicians actually see, but direct experimental proof of the mechanism is limited, and expert review of the autonomic and immune features in hypermobile EDS says as much [26].
We have a separate piece on heart rate variability for anyone tempted to draw firm conclusions from a wearable.
What the overlap changes is management, as someone with both is handling not just joint instability, but load intolerance and pain on top of orthostatic intolerance. And a generic POTS plan that ignores the musculoskeletal half falls over fairly quickly. We see it constantly in the studios: someone told to exercise more, crashing after every session because nobody accounted for the orthostatic side. Understanding what drives flares is often worth more than another intervention.
Exercise Therapy: What the Review Actually Says
Exercise is a first line non pharmacological treatment for POTS, and structured programmes that begin horizontal or semi recumbent and progress towards upright work over roughly three months, have improved heart rate responses, symptoms and quality of life across a number of studies [12][27][28].
Now another caveat, because I do love them, as it matters most for our readers. The evidence base is small, methodologically variable, at real risk of bias, and poorly stratified by comorbidity. And it’s thinnest exactly where you our readers sit: people with hypermobility, ME/CFS features, or prominent post exertional malaise [27][28]. So, the honest version is that the research supports graded exercise as a first line option for POTS and says very little about people who crash for days afterwards, which to be honest, has been an issue for many, many years. It’s not a recent thing.
That isn’t an argument against moving, it’s an argument for starting lower than feels sensible, progressing slower than feels productive, and treating pacing as part of the programme rather than a concession to it. The first step in POTS exercise is usually the one that gets skipped.
Medication isn’t the enemy of any of this either, and for people who can’t tolerate a beta blocker the usual alternative is worth understanding, so we’ve looked at ivabradine for POTS separately.
CO2, Breathing, and POTS: An Early and Unsettled Line of Research
Hypocapnia and reduced cerebral blood flow on standing are genuinely being studied in orthostatic intolerance, and this is also the part of the POTS conversation most likely to be oversold. One line of work proposes that POTS and hypocapnic cerebral hypoperfusion without tachycardia may sit on a spectrum of the same disorder, with reduced orthostatic cerebral blood flow as the unifying feature [22]. The mechanism is intuitive enough: over breathing on standing lowers blood CO2, low CO2 narrows the cerebral vessels, and brain perfusion drops further than posture alone would explain.
It’s being taken seriously, but it’s hypothesis generating rather than consensus, and framing POTS as substantially a respiratory disorder goes beyond what the evidence supports: the old chicken and the egg so to speak [22]. Breathing retraining is not established POTS treatment. It may turn out to be one useful component for some people, particularly where breathlessness dominates, and it may not. But, I am calling it now. For future reference, I think this will do well in research, and answer a lot of questions.
With that caveat firmly attached, CO2 tolerance is a concept we find genuinely useful in practice, and breathing pattern problems are common in hypermobility, for mechanical reasons that have nothing to do with anxiety, although anecdotally, many people do report feeling calmer when increasing there tolerance for Co2.
Multidisciplinary Care
The ideal model is a GP working alongside a clinician highly trained in autonomic medicine, with allied health support, longer appointments and proper follow up. Which is to say: a unicorn with an appointment system. Both the review and earlier consensus work call for exactly this, and both note the shortage of autonomic specialists that makes it unavailable to most people. [5][6][11]. That gap is structural: guideline updates don’t train staff or fund clinics. Practically, it means being strategic, as a GP willing to run a standing test, and a physiotherapist who understands dysautonomia, are usually a lot more reachable than a specialist with a sane waiting list.
Gut symptoms deserve a place in the plan rather than a referral queue of their own, as gastrointestinal problems and systemic comorbidities are common in POTS. Expert review has addressed the gastrointestinal picture in hypermobile EDS specifically [15][26]. Higher up, throat and swallowing problems come up often enough with our clients to be worth raising with whoever coordinates your care.
The psychological load needs stating carefully though. Quality of life in POTS is markedly worse than in matched populations, and having symptoms attributed to anxiety before diagnosis is common rather than rare [7][1][3]. Being worn down by years of that is a response to the circumstances rather than the cause of them. Sadly we have heard many a horror story in our line of work.
Two other things sit alongside all of this and get managed nowhere. If sleep disturbance is part of your picture, raise it directly rather than assuming it’s down the stream of everything else.
Readings at the low end of normal deserve the same treatment. Low blood pressure interacts with fatigue in ways that get missed when all the attention is fixed on heart rate.
What About Long COVID, Paediatric POTS, and HPV Related Cases?
Long COVID is the best supported of these, as observational work reports high rates of autonomic dysfunction after COVID, with a substantial proportion of highly symptomatic people meeting POTS criteria. And that has changed how autonomic services are resourced in some centres [29][30][11]. The qualifier is that reported prevalence varies widely with the cohort studied, and how cases were found, so figures quoted in isolation tell you very little.
Paediatric POTS is not just adult POTS in a smaller body though. The heart rate threshold used in children and adolescents is higher than the adult one, and management has to account for schooling, activity and development rather than just heart rate alone [18][17][25].
HPV needs handling with real care. Cases of POTS reported after HPV vaccination have been discussed in the literature, but this is reported and controversial territory rather than a recognised clinical entity, and causality is not established. The one relevant paper concerns mast cell activation rather than POTS causation, and proposes, as a hypothesis for testing, that vaccination might escalate pre existing undiagnosed mast cell disease in a few people [31].
The Gap
The unresolved question, is how to define biologically meaningful subgroups, particularly around hypermobility, mast cell involvement, long COVID and breathing related cerebral hypoperfusion, in a way that actually improves diagnosis and treatment. That is an open priority, not a solved problem [6][22][13]. Alongside it sits the implementation gap: reviews describe ideal care, and cannot conjure the services to actually deliver it, so access stays the limiting step (surprise, surprise) [5].
Then, there’s the big ole hypermobility shaped hole. The association is acknowledged, but there’s little guidance on modifying exercise programming or management priorities for people with POTS alongside hypermobile EDS or HSD, and the exercise literature has barely studied them as a group [28][27][24]. And it’s the same issue we have spent decades here at The Fibro Guy navigating with our clients.
The mast cell gap is the same story in a different key: studies use varying and often non laboratory definitions, so prevalence and treatment response shift with the criteria chosen [21][20]. On the longer view, follow up extending over decades shows a mixed picture, with improvement common but symptoms frequently persisting rather than resolving cleanly [32][4]. Not comfortable reading I know, but a good deal more useful than simply false reassurance.
What This Means for You, Practically Speaking
– A standing test is a legitimate route to diagnosis: a GP with a cuff and a timer can do the first pass, though tilt testing still has its role when the picture isn’t clear [9][13].
– Your symptom burden is part of the clinical picture: a heart rate number was never designed to capture multisystem symptoms, and consensus work has said so plainly enough [6][15].
– Expect more than one mechanism: low volume, impaired vascular tone, and mast cell involvement can all contribute at once, which is why single intervention plans tend to disappoint [16][12].
– Exercise helps, but the version matters: graded, recumbent start, paced work is a very different thing from being told to walk more, and the evidence is weakest precisely for people with post-exertional malaise [27][28].
– Salt and fluids are subtype dependent: volume expansion is standard first- ine management, and it does a lot more for some people than for others [11][16].
If you’re going through hormonal change alongside all this, it deserves more than a footnote, so we’ve written a rather article about menopause and perimenopause with hypermobility separately.
Closing Thoughts
Read carefully, the review is a useful document. It describes POTS as a heterogeneous, multisystem, high burden condition needing individualised and often multidisciplinary care, rather than a fainting problem or an anxiety problem [5][6]. That’s worth having in writing when you walk into an appointment. What it doesn’t do though, is resolve the field as diagnostic precision. Meaningful subgrouping and the needs of people with hypermobility all remain open, and the distance between recommended care and available care hasn’t really moved [6][27].
On the overlap that brings most of our readers here, the honest position is layered rather than tidy. Hypermobility is clearly overrepresented in POTS cohorts [23][9][25]. Mast cell overlap is much less secure, as reported prevalence swings with the case definition used [21][20]. And a shared mechanistic cause behind all three is not established [20][26]. Three claims, three levels of confidence. Less satisfying than one neat entity, but a great deal more accurate.
If you’ve spent years being told these things are unrelated, the takeaway isn’t that the science has arrived. It’s that the association is real enough to raise with a clinician, the mechanism is genuinely unsettled, and you’re entitled to be told which is which.
You shouldn’t have to fight this hard, but I hope this article has at least cleared something up for you, and pointed you in the right direction.
Until next time.
The Fibro Guy
